Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma (OAG)
Interventions: DSLT enables newly diagnosed patients to remain well controlled and off medications; Device
Lead sponsor: Barnet Dulaney Perkins Eye Centers; Network
Eligibility: 30 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Glaucoma
Interventions: Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Newport Beach, California • Largo, Florida • Miami, Florida + 7 more

Conditions: Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions: Collection of genetic material; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 1,152 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Microstent, Cataract surgery, Monofocal IOL; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 22
States / cities: Irvine, California • Sacramento, California • Loveland, Colorado + 19 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 2 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 47
States / cities: Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more

Conditions: Glaucoma
Interventions: POLAT-001, Latanoprost ophthalmic solution; Drug
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions: Travaprost without BAC (Travatan Z); Drug
Lead sponsor: United States Air Force; Federal
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Open-Angle Glaucoma
Interventions: iStent plus Cataract Surgery, Cataract surgery only; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 31
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 27 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: T-2345, Xalatan; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System, iStent inject; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dothan, Alabama • Vineland, New Jersey

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 2,597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions: Timolol Maleate, Brimonidine Tartrate; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Interventions: Travoprost; Combination Product
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kenosha, Wisconsin

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine purite 0.15%, Dorzolamide 2%, Brinzolamide 1%; Drug
Lead sponsor: Northwestern Ophthalmic Institute S.C.; Other
Eligibility: 41 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Glaucoma
Interventions: iStent Inject (GTS400), Cataract Surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Artesia, California • Los Angeles, California • Torrance, California + 9 more

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Aqueous Implant, Cataract surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more

Conditions: Primary Open Angle Glaucoma, Healthy Subjects
Interventions: SENSIMED Triggerfish; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Hydrus® Microstent New Enrollment Post-Approval Study

Evaluation of Safety and Efficacy of PDP-716

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

Advanced Glaucoma Progression Study

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor